Mevlyq

Eribulin mesylate, the active ingredient in Mevlyq, is a Halichondrin B analog presented as an intravenous formulation for use in patients with certain cancers. It is indicated for metastatic breast cancer and for liposarcoma, where it targets rapidly dividing tumor cells.

GNH USA supplies Mevlyq as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mevlyq (eribulin mesylate) is used in the treatment of solid tumours that are driven by rapid cell division. - Metastatic breast cancer: improves progression‑free survival in patients previously treated with anthracyclines and taxanes. - Unresectable or metastatic liposarcoma: provides disease control in patients with advanced soft‑tissue sarcoma.

Eribulin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count leading to infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: feeling of sickness often accompanied by vomiting. - Peripheral neuropathy: tingling or numbness in the hands and feet.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Pulmonary toxicity: difficulty breathing or interstitial lung disease. - Severe hepatic dysfunction: marked elevation of liver enzymes or liver failure.

When using Mevlyq, clinicians should observe several safety measures to minimize risk. - Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: perform baseline ECG and monitor for arrhythmias. - Avoid in severe neutropenia: do not administer if absolute neutrophil count is critically low. - Use caution with pre‑existing neuropathy: adjust dosing if peripheral nerve symptoms are present. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eribulin can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase eribulin exposure. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce eribulin plasma levels. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk. - Drugs causing peripheral neuropathy (e.g., vincristine): increase likelihood of nerve toxicity.